Association between c-myc amplification and pathological complete response to neoadjuvant chemotherapy in breast cancer
Autor: | Kazuki Kishi, Yasuto Naoi, Seung Jin Kim, Atsushi Shimomura, Yasuhiro Tamaki, Shinzaburo Noguchi, Yousuke Baba, Takahiro Nakayama, Kenzo Shimazu, Hiroyuki Yasojima |
---|---|
Rok vydání: | 2011 |
Předmět: |
Oncology
Cancer Research Receptor ErbB-2 medicine.medical_treatment Biopsy chemistry.chemical_compound Antineoplastic Combined Chemotherapy Protocols Odds Ratio Poly-ADP-Ribose Binding Proteins In Situ Hybridization Fluorescence Oligonucleotide Array Sequence Analysis Middle Aged Immunohistochemistry Neoadjuvant Therapy DNA-Binding Proteins Gene Expression Regulation Neoplastic Treatment Outcome Paclitaxel Receptors Estrogen Chemotherapy Adjuvant Lymphatic Metastasis Female Fluorouracil Ultrasonography Mammary Receptors Progesterone Epirubicin medicine.drug Adult medicine.medical_specialty Cyclophosphamide Breast Neoplasms Proto-Oncogene Proteins c-myc Breast cancer Antigens Neoplasm Predictive Value of Tests Internal medicine Progesterone receptor medicine Biomarkers Tumor Humans Aged Neoplasm Staging Retrospective Studies Chemotherapy Analysis of Variance business.industry Gene Expression Profiling Gene Amplification Cancer medicine.disease DNA Topoisomerases Type II Ki-67 Antigen chemistry business |
Zdroj: | European journal of cancer (Oxford, England : 1990). 47(12) |
ISSN: | 1879-0852 |
Popis: | Background The aim of this study was to investigate whether c-myc amplification in human breast cancer is associated with response to neoadjuvant chemotherapy comprising paclitaxel followed by 5-FU/epirubicin/cyclophosphamide (P-FEC). Methods Tumour tissue samples were obtained before neoadjuvant chemotherapy (P-FEC) from 100 primary breast cancer patients (stage II/III). C-myc and HER2 amplification were examined by FISH, and oestrogen receptor (ER), progesterone receptor (PR), Ki67, and topoisomerase 2α (TOP2A) expression were examined immunohistochemically. Pathological complete response (pCR) was defined by a complete loss of tumour cells in the breast without any lymph node metastasis. Results C-myc amplification was observed in 40% (40/100) of breast tumours, and was significantly associated with ER-negative tumours (23/40 for ER(–) versus 17/60 for ER(+), P = 0.004), high histological grade tumours (11/18 for grade 3 versus 29/82 for grades 1 + 2, P = 0.043) and TOP2A-positive tumours (28/51 for TOP2A(+) versus 12/49 for TOP2A(–), P = 0.002). pCR rate was 20% for total patients (10.0% for ER(+) and 35.0% for ER(–)). Further, breast tumours with c-myc amplification (c-myc(+)) showed a significantly (P = 0.041) higher pCR rate (12/40) than those without such amplification (c-myc(–)) (8/60). This association between pCR and c-myc amplification was observed in ER-positive tumours (4/17 for c-myc(+) versus 2/43 for c-myc(–), P = 0.048) but not in ER-negative tumours (8/23 for c-myc(+) versus 6/17 for c-myc(–), P = 0.973). Conclusion Our results suggest that c-myc amplification is significantly associated with a high pCR rate to P-FEC in breast tumours, especially in ER-positive tumours. |
Databáze: | OpenAIRE |
Externí odkaz: |